Armstrong J M, Vitetta E S
Department of Microbiology and Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas 75235-8576, USA.
Int J Cancer. 1996 Dec 11;68(6):822-7. doi: 10.1002/(SICI)1097-0215(19961211)68:6<822::AID-IJC22>3.0.CO;2-0.
The aim of this study was to construct bispecific F(ab')2 [anti-CD3 x anti-BCL1 idiotype (Id)] Abs (BsAbs) which would enable lymphokine-activated killer (LAK) T cells to kill Id+ mouse BCL1 lymphoma cells, and to determine the mechanism(s) underlying cell death. Using 4-day activated LAK T cells from either perforin-knockout mice or FasL-deficient gld mice, we show that the Fas pathway, but not perforin, is required for BsAb-mediated LAK T-cell-induced killing of BCL1 cells.